HERTFORDSHIRE, England and
PITTSBURGH, Oct. 26, 2016 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL) today announced the U.S. launches of the first
generic versions of Daiichi Sankyo's Benicar® and Benicar HCT®,
Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, and Olmesartan
Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40
mg/12.5 mg, and 40 mg/25 mg, respectively. Mylan received final
approval from the U.S. Food and Drug Administration (FDA) for its
Abbreviated New Drug Applications (ANDA) for these products.
Olmesartan Medoxomil Tablets are indicated for the treatment of
hypertension, along or with other antihypertensive agents, to lower
blood pressure. Olmesartan Medoxomil and Hydrochlorothiazide
Tablets are indicted for the treatment of hypertension to lower
blood pressure, and are not indicated for the initial therapy of
hypertension. (1)
Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, had U.S.
sales of approximately $1 billion for
the 12 months ending August 31, 2016,
according to IMS Health. Olmesartan Medoxomil and
Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40
mg/25 mg had U.S. sales of approximately $805 million during that same time.
Currently, Mylan has 237 ANDAs pending FDA approval representing
$94.4 billion in annual brand sales,
according to IMS Health. Forty-one of these pending ANDAs are
potential first-to-file opportunities, representing $32.5 billion in annual brand sales, for the 12
months ending June 30, 2016,
according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 2,700 generic and branded pharmaceuticals,
including antiretroviral therapies on which approximately 50% of
people being treated for HIV/AIDS worldwide depend. We market our
products in more than 165 countries and territories. Our global
R&D and manufacturing platform includes more than 50
facilities, and we are one of the world's largest producers of
active pharmaceutical ingredients. Every member of our more than
40,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com.
(1) When pregnancy is detected, discontinue as soon as possible.
Drugs that act directly on the renin-angiotensin system can cause
injury and death to the developing fetus.
Logo - http://photos.prnewswire.com/prnh/20140423/77793
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-first-generics-of-benicar-and-benicar-hct-tablets-300351810.html
SOURCE Mylan N.V.